FLT3 and acute myeloid leukemia: Gilteritinib is a selective second-generation FLT3 inhibitor, with a high overall response rate (ORR, 52%) in FLT3mut+ AML patients, and more than 90% of FLT3 signaling inhibition was observed in most patients receiving a daily dose of 80 mg gilteritinib (Perl et al., 2017).